AUTHORS
Jenna Oberg, Keith McCrae, MD2, Thomas L. Ortel, MD, PhD3, Yves Gruel4, Jérôme Rollin, PhD5, Rumi Clare, BSc6, Ishac Nazy, PhD7, Roxanne Cofiell8, Geoffrey Wool, MD, PhD9, Freda Janet Passam, MD,PhD10, Kandace Gollomp, MD11, Douglas Cines Sr, Prof12, Gowthami Arepally, MD13, Sungkwon Kim, PhD14, Lubica Rauova, MD, PhD15, Mortimer Poncz, MD16, Amrita Sarkar, PhD17
AFFILIATIONS
1 Children's Hospital of Philadelphia, Philadelphia, United States
2 The Cleveland Clinic Foundation, Cleveland, United States
3 Duke University, Durham, United States
4 University Hospital of Tours, and INSERM UMR1327, Tours, France
5 University Hospital of Tours, Tours, France
6 McMaster University, Ontario, Canada
7 McMaster University, Ontario, Canada
8 Alexion Pharmaceutical, Boston, United States
9 University of Chicago, Chicago, United States
10 University of Sydney, Sydney, Australia
11 Children's Hospital of Philadelphia, Philadelphia, United States, University of Pennsylvania, Philadelphia, United States
12 University of Pennsylvania, Philadelphia, United States
13 Duke University, Durham, United States
14 Alexion Pharmaceutical, Boston, United States
15 Children's Hospital of Philadelphia, Philadelphia, United States, University of Pennsylvania, Philadelphia, United States
16 Children's Hospital of Philadelphia, Philadelphia, United States, University of Pennsylvania, Philadelphia, United States
17 Children's Hospital of Philadelphia, Philadelphia, United States, University of Pennsylvania, Philadelphia, United States
ABSTRACT
Background: Heparin-induced thrombocytopenia (HIT), vaccine-induced immune thrombotic thrombocytopenia (VITT), and antiphospholipid syndrome (APS) are PF4-centric immunothrombotic disorders characterized by pathogenic antibodies that induce thrombosis through FcγRIIA-dependent cellular activation. Our group and others have shown that platelet factor 4 (PF4) bound to von Willebrand factor (VWF) strings and neutrophil extracellular traps (NETs) forms dense antigenic scaffolds that promote pathogenic antibody binding, and platelet and complement activation in HIT and VITT. In APS, β2-glycoprotein I (β2GPI), a known PF4-binding partner, facilitates formation of similar pathogenic antigenic triplexes as we recently reported (PMID:42378231). We hypothesized that terminal complement activation is a shared driver of thrombosis across these disorders and that C5 inhibition would attenuate both thromboinflammatory mechanisms in vitro and disease manifestations in vivo.
Aims: To investigate the role of terminal complement activation in PF4-mediated immunothrombosis and evaluate the effects of C5 inhibition in in vitro and in vivo models of HIT, VITT, and APS.
Methods: Photochemically injured HUVEC-lined microfluidic channels were used to generate VWF strings and adhesion of platelets (Plts) on VWF strings, and complementary neutrophil-based microfluidic systems were used to assess NET-associated thrombosis. Whole blood from healthy donors was incubated with PF4 (25 μg/mL) and purified patient HIT, VITT, or APS IgG (100 μg/mL) with or without eculizumab (10 or 15 μg/mL). Platelet activation, complement deposition, and NET formation were evaluated. The contribution of VWF strings and NETs was investigated using ADAMTS13 and DNase1, respectively. For in vivo studies, FcγRIIA+/hPF4+/mPF4−/− (termed as hPFm) mice received anti-mouse C5 antibody BB5.1 (100μg) prior to administration of the HIT-like anti-PF4 monoclonal antibody KKO (1.5μg/g.) Platelet counts and venular neutrophil rolling and thrombosis within cremaster vessels were assessed.
Results: In vitro, eculizumab demonstrated dose-dependent inhibition of PF4-mediated platelet activation. Both 10 and 15 μg/mL eculizumab inhibited HIT and APS-mediated platelet activation, whereas inhibition of VITT-mediated platelet activation was seen at the higher dose. Dose-dependent reductions were observed in complement deposition. Eculizumab (15 μg/mL) inhibited NET formation induced by HIT, VITT, and APS IgG. Furthermore, disruption of VWF strings with ADAMTS13 and degradation of NETs with DNase1 significantly reduced platelet activation, supporting a model in which PF4 bound to VWF strings and NETs serves as critical antigenic scaffolds for pathogenic antibody binding and complement amplification.
In the in vivo HIT model in hPFm mice, prophylactic administration of BB5.1 attenuated KKO-induced thrombocytopenia and significantly reduced neutrophil rolling within cremaster venules. BB5.1, both by prophylaxis and therapeutic intervention reduced arterial and venous thrombosis.
Conclusions: PF4-centric immunothrombotic disorders, which now includes APS, share a common pathway in which PF4 bound to NETs or VWF promotes pathogenic antibody binding, complement activation, and thromboinflammatory amplification. In all three disorders, terminal complement inhibition suppresses platelet activation, complement deposition, and NET formation in vitro and protects against thrombocytopenia, vascular inflammation and thrombosis in HIT in vivo. These findings identify C5-dependent complement activation as a critical therapeutic target in HIT, VITT, and APS and provide a rationale for complement-directed interventions to prevent immunothrombosis.
DISCLOSURES
Jenna Oberg: No relevant conflicts of interest to declare.